FDA Approves IV Secukinumab On 10/6/23, Novartis announced the FDA approved an IV formulation of secukinumab (Cosentyx) for use in treating adults with PsA, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) https://t.co/zv7b98ZUjS https://t.co/1rXjYIbLpw